BioSpace News Archive

Therapeutics Solutions International, Inc., (OTC Markets: TSOI), reported today positive preclinical data demonstrating superior neuro-regenerative activity to other cell therapies such as mesenchymal stem cells.

Paragonix Technologies announced that its Paragonix SherpaPak™ Cardiac Transport System (CTS) for donor heart preservation and transport is now being used by Stanford Health Care, the first heart transplant center on the West Coast of the United States to implement the system as standard of care for its heart transplant program.

Animalcare to Invest $5 million , Consisting of $ 3 million to Acquire One-Third Stake in STEM Animal Health, Kane Biotech’s New Animal Health Subsidiary , and $2 million for R ight s to C ommercialize P roducts in Global V eterinary M arkets Outside of the Americas Animalcare to Launch Biofilm Oral Care Range for Companion Animals in European and Asian Markets WINNIPEG, Manitoba, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Kane Biotech I

XtalPi, an Artificial Intelligence (AI) drug discovery and development technology company, today announces an oversubscribed Series C funding of $318.8 million co-led by SoftBank Vision Fund 2i, PICC Capital, and Morningside.

From the Science of Beer to learning about the benefits of GMOs; Saskatchewan is celebrating science with exciting online events and activities that showcase the province’s bioscience sector.

AscellaHealth, a national specialty pharmacy benefit manager (SPBMTM) serving commercial, Medicare and Medicaid segments, was ranked 6th on the Philadelphia Business Journal’s 2019 “Soaring 76” list of fastest-growing companies in greater Philadelphia region as measured by revenue over a three-year period from 2017 through 2019.

Accent Therapeutics today announced that it has been named by Fierce Biotech as one of 2020’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Accent is a leader in the development of small molecule therapies that selectively inhibit RNA-modifying proteins (RMPs) that drive cancer. By targeting RMPs, the company is taking a novel appr

FibroGenesis, the leading developer of fibroblast based therapeutic solutions for unmet medical needs, is pleased to announce it has entered into a manufacturing agreement with iBiologics to supply its proprietary allogeneic fibroblast ce

Partnerships are on Diaceutics’ DXRX platform – the world’s first diagnostic network for precision medicine Platform, launching in Q4 2020, has been purpose built to enable collaboration between key stakeholders in precision medicine to solve real-world biomarker testing issues Pharmaceutical companies will gain greater oversight of diagnostic testing standards for their new and planned precision medicines Will enable individu

Aligos Therapeutics, Inc. (Aligos), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the Company has received approval for a clinical trial application (CTA) for a first-in-human Phase 1a/b proof-of-concept clinical trial. Aligos may now commence study ALG-000184-201 (NCT04536337) to evaluate ALG-000184, a small mole